Biohaven .(US:BHVN) Prnewswire·2025-08-21 12:45Core Points - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit related to misleading statements made by the company during the class period from March 24, 2023, to May 14, 2025 [1] - Allegations include overstated regulatory prospects for the product candidate troriluzole and its efficacy for treating bipolar disorder, which may negatively impact Biohaven's business and financial condition [1] - Shareholders are encouraged to register for the class action by the deadline of September 12, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Company Information - Biohaven Ltd. is facing allegations of issuing materially false and misleading statements regarding its product candidates, which could lead to significant financial repercussions [1] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to the company's alleged deceitful practices [3] Next Steps for Shareholders - Shareholders who purchased shares of Biohaven during the specified class period should register to participate in the class action, with no cost or obligation involved [2] - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]